BACKGROUND: Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that these medications can also paradoxically induce a psoriasiform skin reaction in a subset of patients. GOALS: We seek to share our experience in treating severe TNF inhibitor-induced psoriasis in a pediatric patient with Crohn’s disease. STUDY: We report a case of a 10-year-old female with Crohn’s disease, who developed psoriasis after twelve months of infliximab therapy. Her skin disease was recalcitrant to topical therapies, methotrexate, and phototherapy. RESULTS: The patient was transitioned to ustekinumab with significant improvement in her symptoms and maintenance of remission of her bowel disease. CONCLUSION: This is the first reported case of a school-age pediatric patient with TNF inhibitor-induced psoriasis treated with ustekinumab. Controlled trials are warranted to fully assess the safety and efficacy of ustekinumab for treating TNF inhibitor-induced psoriasis in the pediatric population.J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.2106.
BACKGROUND:Tumor necrosis factor (TNF) inhibitors are widely used in pediatric patients with inflammatory bowel disease, as well as psoriasis. However, there is growing evidence that these medications can also paradoxically induce a psoriasiform skin reaction in a subset of patients. GOALS: We seek to share our experience in treating severe TNF inhibitor-induced psoriasis in a pediatric patient with Crohn’s disease. STUDY: We report a case of a 10-year-old female with Crohn’s disease, who developed psoriasis after twelve months of infliximab therapy. Her skin disease was recalcitrant to topical therapies, methotrexate, and phototherapy. RESULTS: The patient was transitioned to ustekinumab with significant improvement in her symptoms and maintenance of remission of her bowel disease. CONCLUSION: This is the first reported case of a school-age pediatric patient with TNF inhibitor-induced psoriasis treated with ustekinumab. Controlled trials are warranted to fully assess the safety and efficacy of ustekinumab for treating TNF inhibitor-induced psoriasis in the pediatric population.J Drugs Dermatol. 2020;19(3): doi:10.36849/JDD.2020.2106.
Authors: Iván Guerra; Tamara Pérez-Jeldres; Marisa Iborra; Alicia Algaba; David Monfort; Xavier Calvet; María Chaparro; Miriam Mañosa; Esther Hinojosa; Miguel Minguez; Jone Ortiz de Zarate; Lucía Márquez; Vanessa Prieto; Valle García-Sánchez; Jordi Guardiola; G Esther Rodriguez; María Dolores Martín-Arranz; Iván García-Tercero; Beatriz Sicilia; Ángeles Masedo; Rufo Lorente; Montserrat Rivero; Luis Fernández-Salazar; Ana Gutiérrez; Manuel Van Domselaar; Antonio López-SanRomán; Yolanda Ber; Marifé García-Sepulcre; Laura Ramos; Fernando Bermejo; Javier P Gisbert Journal: Inflamm Bowel Dis Date: 2016-04 Impact factor: 5.325
Authors: Cornelia Tillack; Laura Maximiliane Ehmann; Matthias Friedrich; Rüdiger P Laubender; Pavol Papay; Harald Vogelsang; Johannes Stallhofer; Florian Beigel; Andrea Bedynek; Martin Wetzke; Harald Maier; Maria Koburger; Johanna Wagner; Jürgen Glas; Julia Diegelmann; Sarah Koglin; Yvonne Dombrowski; Jürgen Schauber; Andreas Wollenberg; Stephan Brand Journal: Gut Date: 2013-03-06 Impact factor: 23.059